2023. Anti-PD-1 immune checkpoint blockade-based therapy using pembrolizumab in a patient with high-grade glioblastoma. Biomedical Research and Therapy. 10, 5 (May 2023), 5680–5685. DOI:https://doi.org/10.15419/bmrat.v10i5.809.